US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Birth Control

2,809.53

+37.321.35%

Number of Gainers:4

Number of Losers:1

Number of Flat:- -

PE:- -

High:2,843.20

Open:2,773.64

Low:2,762.59

Close:2,772.21

Volume:8.62M

Turnover:176.88M

Market Cap:44.92B

Float Cap:41.95B

Loading ...

Daré Bioscience to Issue Series A, Series B Warrants in Private Placement for up to 8,759,162 Shares

NASDAQ Trade Halt Volatility Trading Pause at 12:45 Pm

DarÉ Bioscience Announces Pricing of $6.0 Million Registered Direct Offering Priced At-the-Market Under NASDAQ Rules

THOMSON REUTERS

Daré Bioscience Announces Pricing of $6.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

VistaGen Q1 Revenue Rises on Licensing Agreement Expiration

Dare Bioscience Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Dare Bioscience, Inc. Q2 EPS USD -0.2

THOMSON REUTERS

Daré Bioscience Q2 FY26 Net Loss Narrows to $2.98 Million; Revenue Rises to $187,546

DarÉ Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women’s Health Strategy Advances

THOMSON REUTERS

Daré Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women’s Health Strategy Advances

Femasys Inc : Maxim Group Adjusts Target Price to $10 from $30 to Reflect 1-for-20 Reverse Stock Split

THOMSON REUTERS

Femasys Strengthens and Extends Global Patent Protection for FemBloc® with First Issued Blended Polymer Patents

Femasys Files Form 3 for Chief Clinical-Medical Affairs Jeffrey Gerald Mifek

Femasys CEO Kathy Lee-Sepsick Acquires USD 50,000 in Common Shares

Femasys completes $30 million private placement financing

Dare Bioscience Inc Expected to Post a Loss of 24 Cents a Share - Earnings Preview

Femasys Raih Sekitar USD 30 Juta Lewat Private Placement Saham Dan Waran

Femasys Inc Expected to Post a Loss of $1.30 a Share - Earnings Preview

MannKind Director Steven B. Binder Sells 39,051 Shares Worth $158,547

Is MannKind (MNKD) Undervalued After Positive INFLO 1 Data For Its IPF Pipeline?

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/BK4584/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4584","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4584\",,,,,undefined,":{"symbol":"BK4584","market":"US","secType":"PLATE","nameCN":"Birth Control","latestPrice":2809.5261,"timestamp":1787342399999,"preClose":2772.205,"halted":0,"volume":8615466,"delay":0,"changeRate":0.013463,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":37.321045,"latestTime":"08-21 16:00:00 EDT","open":2773.6416,"high":2843.2031,"low":2762.586,"amount":176883492.694548,"amplitude":0.029081,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":5.743837,"peRate":70.810459,"turnoverRate":0.005996,"increases":4,"decrements":1,"flats":0,"marketCap":44921179196,"floatMarketCap":41949345425},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4584\",,,,,undefined,":{"symbol":"BK4584","high":2843.2031,"amplitude":0.029081,"preClose":2772.205,"low":2762.586,"pbRate":"5.743837","latestPrice":2809.5261,"volume":8615466,"delay":0,"open":2773.6416,"prevYearClose":2379.9924,"prevWeekClose":2762.5803,"prevMonthClose":2636.2712,"prevQuarterClose":2562.5076,"fiveDayClose":2762.5803,"twentyDayClose":2335.9458,"sixtyDayClose":2579.5955,"secType":"PLATE","market":"US","turnoverRate":0.005996,"peRate":70.810459,"marketCap":44921179196,"floatMarketCap":41949345425,"timestamp":1787342399999,"nameCN":"Birth Control"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4584\",,,,undefined,":{"bkCode":"BK4584","up":4,"down":1,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4584\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2659123955","title":"Daré Bioscience to Issue Series A, Series B Warrants in Private Placement for up to 8,759,162 Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2659123955","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659123955?lang=en_us&edition=fundamental","pubTime":"2026-08-15 00:45","pubTimestamp":1786725920,"startTime":"0","endTime":"0","summary":"Daré Bioscience to issue Series A, Series B warrants in private placement for up to 8,759,162 sharesDaré Bioscience set a concurrent private placement of Series A warrants, Series B warrants, and unde","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDLTx7Zt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","BK4007","SG9999014039.USD","IE00BN0W2V16.EUR","BK4584","BK4588","BCDF","IE00BN0W2W23.USD","LU2095319765.USD","NDAQ","IE00BGHQF748.EUR","LU0314104364.USD","IE00BN0W2T93.GBP","BK4112","BK4585","LU2210149790.SGD","LU2210150020.SGD","IE00B64PRP62.GBP","SG9999014013.SGD","SG9999014005.SGD","SG9999014021.USD","DARE","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659312395","title":"NASDAQ Trade Halt Volatility Trading Pause at 12:45 Pm","url":"https://stock-news.laohu8.com/highlight/detail?id=2659312395","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659312395?lang=en_us&edition=fundamental","pubTime":"2026-08-15 00:45","pubTimestamp":1786725918,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALTVOLATILITY TRADING PAUSE AT 12:45 PM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nAQN2METN0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DARE","BK4584","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659932123","title":"DarÉ Bioscience Announces Pricing of $6.0 Million Registered Direct Offering Priced At-the-Market Under NASDAQ Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2659932123","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659932123?lang=en_us&edition=fundamental","pubTime":"2026-08-15 00:45","pubTimestamp":1786725904,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nTUA501QB8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4584","DARE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659250951","title":"Daré Bioscience Announces Pricing of $6.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2659250951","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659250951?lang=en_us&edition=fundamental","pubTime":"2026-08-15 00:45","pubTimestamp":1786725900,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Aug.  14, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (Nasdaq: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising scienc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/14/3345541/30757/en/dar%C3%A9-bioscience-announces-pricing-of-6-0-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LCLG","DARE","BK4007","BK4584"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659416751","title":"VistaGen Q1 Revenue Rises on Licensing Agreement Expiration","url":"https://stock-news.laohu8.com/highlight/detail?id=2659416751","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659416751?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:44","pubTimestamp":1786711464,"startTime":"0","endTime":"0","summary":"VistaGen Q1 revenue rises onlicensing agreement expirationOverviewUS biopharma firm's fiscal Q1 revenue rose, driven by licensing agreement expirationNet loss for fiscal Q1 narrowed from prior year as","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nL1N44B0G0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VTGN","DARE","CELC","BK4539","BK4584","RANI","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659160280","title":"Dare Bioscience Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2659160280","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659160280?lang=en_us&edition=fundamental","pubTime":"2026-08-14 05:01","pubTimestamp":1786654862,"startTime":"0","endTime":"0","summary":"Dare Bioscience Inc reports results for the quarter ended June 30 - Earnings SummaryDare Bioscience IncDARE.OQreported a quarterly adjusted loss of 20 cents per share for the quarter ended June 30, hi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL8N44A27R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4584","DARE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162031","title":"Dare Bioscience, Inc. Q2 EPS USD -0.2","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162031","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162031?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:15","pubTimestamp":1786652153,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nPLX1V7KKP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4584","DARE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659164049","title":"Daré Bioscience Q2 FY26 Net Loss Narrows to $2.98 Million; Revenue Rises to $187,546","url":"https://stock-news.laohu8.com/highlight/detail?id=2659164049","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659164049?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:02","pubTimestamp":1786651323,"startTime":"0","endTime":"0","summary":"Daré Bioscience Q2 FY26 net loss narrows to $2.98 million; revenue rises to $187,546Daré Bioscience posted a Q2 net loss of $2.98 million, narrowing from $4.02 million a year earlier; loss per share i","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL5kjHKQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","SG9999014013.SGD","BK4007","LU2095319765.USD","BK4112","SG9999014005.SGD","BK4588","SG9999014021.USD","IE00BN0W2T93.GBP","LU2210150020.SGD","IE00BGHQF748.EUR","BK4584","IE00BKPKM429.USD","IE00B64PRP62.GBP","IE00BN0W2W23.USD","BK4585","IE00BN0W2V16.EUR","LU0314104364.USD","NDAQ","IE00B3QW5Z07.USD","DARE","BCDF","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659746164","title":"DarÉ Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women’s Health Strategy Advances","url":"https://stock-news.laohu8.com/highlight/detail?id=2659746164","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659746164?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:01","pubTimestamp":1786651261,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nTUABS7Q1Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DARE","BK4007","BK4584"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659857162","title":"Daré Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women’s Health Strategy Advances","url":"https://stock-news.laohu8.com/highlight/detail?id=2659857162","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659857162?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:01","pubTimestamp":1786651260,"startTime":"0","endTime":"0","summary":"Company launches Flora Sync LF5, the company's first directly commercialized product, began generating revenue in July DARE to PLAY Sildenafil Cream progressing toward national dispensing and initial ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/13/3344879/30757/en/dar%C3%A9-bioscience-reports-second-quarter-2026-results-and-highlights-commercial-inflection-as-multi-product-women-s-health-strategy-advances.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","BK4007","LABU","BK4588","BK4585","DARE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659168237","title":"Femasys Inc : Maxim Group Adjusts Target Price to $10 from $30 to Reflect 1-for-20 Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2659168237","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659168237?lang=en_us&edition=fundamental","pubTime":"2026-08-13 22:23","pubTimestamp":1786630998,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nFWN44A1AK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","FEMY","BK4584","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658890890","title":"Femasys Strengthens and Extends Global Patent Protection for FemBloc® with First Issued Blended Polymer Patents","url":"https://stock-news.laohu8.com/highlight/detail?id=2658890890","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658890890?lang=en_us&edition=fundamental","pubTime":"2026-08-12 21:00","pubTimestamp":1786539600,"startTime":"0","endTime":"0","summary":"-- New U.S. and international patents complement existing delivery system patents, extending global IP coverage for the FemBloc solution -- ATLANTA, Aug.  12, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NA","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/12/3343690/0/en/femasys-strengthens-and-extends-global-patent-protection-for-fembloc-with-first-issued-blended-polymer-patents.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","FEMY","BK4082","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658942811","title":"Femasys Files Form 3 for Chief Clinical-Medical Affairs Jeffrey Gerald Mifek","url":"https://stock-news.laohu8.com/highlight/detail?id=2658942811","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658942811?lang=en_us&edition=fundamental","pubTime":"2026-08-12 08:48","pubTimestamp":1786495702,"startTime":"0","endTime":"0","summary":"Femasys files Form 3 for Chief Clinical-Medical Affairs Jeffrey Gerald MifekFemasys Chief Clinical-Medical Affairs Jeffrey Gerald Mifek reported direct ownership of 1,411 common shares in an initial F","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDL4jpL8t:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","FEMY","BK4082","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658794447","title":"Femasys CEO Kathy Lee-Sepsick Acquires USD 50,000 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2658794447","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658794447?lang=en_us&edition=fundamental","pubTime":"2026-08-12 08:31","pubTimestamp":1786494699,"startTime":"0","endTime":"0","summary":"Femasys CEO Kathy Lee-Sepsick acquires USD 50,000 in common sharesFemasys CEO Kathy Lee-Sepsick bought 15,625 common shares at USD 3.2 each, a USD 50,000 purchase.Her direct common-share stake rose to","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDL4swyDZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Femasys CEO Kathy Lee-Sepsick Acquires USD 50,000 in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FEMY","BK4082","BK4539","BK4584"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658946679","title":"Femasys completes $30 million private placement financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2658946679","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658946679?lang=en_us&edition=fundamental","pubTime":"2026-08-12 05:22","pubTimestamp":1786483359,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Femasys ( ($FEMY) ). On August 7, 2026, Femasys Inc. entered into a securities purchase agreement with accredit...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/femasys-completes-30-million-private-placement-financing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/femasys-completes-30-million-private-placement-financing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4584","BK4539","FEMY","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658194572","title":"Dare Bioscience Inc Expected to Post a Loss of 24 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2658194572","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658194572?lang=en_us&edition=fundamental","pubTime":"2026-08-12 05:04","pubTimestamp":1786482245,"startTime":"0","endTime":"0","summary":"Dare Bioscience Inc <DARE.OQ> expected to post a loss of24cents a share - Earnings PreviewDare Bioscience IncDARE.OQDARE.Ois expected to  show a rise in quarterly revenue when it reports  results on A","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL8N448274:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DARE","BK4584"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658945590","title":"Femasys Raih Sekitar USD 30 Juta Lewat Private Placement Saham Dan Waran","url":"https://stock-news.laohu8.com/highlight/detail?id=2658945590","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658945590?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:41","pubTimestamp":1786480862,"startTime":"0","endTime":"0","summary":"Femasys raih sekitar USD 30 juta lewat private placement saham dan waranFemasys Inc. menutup private placement pada 10 Agustus 2026 dengan target dana kotor sekitar USD 30 juta.Perusahaan menerbitkan ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDL5SLZLq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4082","FEMY","BK4584"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658386992","title":"Femasys Inc Expected to Post a Loss of $1.30 a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2658386992","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658386992?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:05","pubTimestamp":1786446320,"startTime":"0","endTime":"0","summary":"Femasys Inc <FEMY.OQ> expected to post a loss of $1.30 a share - Earnings PreviewFemasys IncFEMY.OQFEMY.Ois expected to  show a rise in quarterly revenue when it reports  results on August 13 (estimat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL8N4480UC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","BK4539","BK4082","FEMY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658638729","title":"MannKind Director Steven B. Binder Sells 39,051 Shares Worth $158,547","url":"https://stock-news.laohu8.com/highlight/detail?id=2658638729","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658638729?lang=en_us&edition=fundamental","pubTime":"2026-08-11 08:45","pubTimestamp":1786409128,"startTime":"0","endTime":"0","summary":"MannKind director Steven B. Binder sells 39,051 shares worth $158,547MannKind director Steven B. Binder sold 39,051 common shares on Aug. 7, 2026 at a weighted average price of $4.06.Binder’s direct s","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDL6fDR3d:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"MannKind Director Steven B. Binder Sells 39,051 Shares Worth $158,547","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNKD","BK4584","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658952917","title":"Is MannKind (MNKD) Undervalued After Positive INFLO 1 Data For Its IPF Pipeline?","url":"https://stock-news.laohu8.com/highlight/detail?id=2658952917","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658952917?lang=en_us&edition=fundamental","pubTime":"2026-08-11 03:42","pubTimestamp":1786390964,"startTime":"0","endTime":"0","summary":"MannKind (MNKD) recently drew investor attention after reporting positive topline Phase 1b INFLO-1 data for its inhaled nintedanib therapy in idiopathic pulmonary fibrosis patients, highlighting safety, tolerability, and effective deep lung delivery.\nSee our latest analysis for MannKind.\nThe INFLO-1 update has come alongside a sharp move in MannKind’s stock, with a 1-day share price return of 5.66% and a 90-day share price return of 25.30%. However, the year-to-date share price return is down...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mnkd/mannkind/news/is-mannkind-mnkd-undervalued-after-positive-inflo-1-data-for","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mnkd/mannkind/news/is-mannkind-mnkd-undervalued-after-positive-inflo-1-data-for","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4584","MNKD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":54,"code":"91000000","status":"200"}]}}